Looking to expand its mRNA franchise, Pfizer (NYSE:PFE) announced a pact with Acuitas, which specializes in lipid nanoparticle (LNP) formulation technology. The deal allows Pfizer to license Acuitas’ LNP technology in up to 10 targets for vaccine or therapeutic development. Pfizer and its partner BioNTech currently use Acuitas’ LNP in their Comirnaty COVID-19 vaccine. Pfizer…